期刊文献+

Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease 被引量:9

Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease
暂未订购
导出
摘要 AIM: To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole,bismuth subcitrate,furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success.METHODS: Open cohort study which included patients with peptic ulcer who had previously been treated unsuccessfully with one or more eradication regimens.The therapeutic regimen consisted of 20 mg omeprazole,240 mg colloidal bismuth subcitrate,1000 mg amoxicillin,and 200 mg furazolidone,taken twice a day for 7 d.Patients were considered as eradicated when samples taken from the gastric antrum and corpus 12 wk after the end of treatment were negative for Helicobacter pylori (H pylori) (rapid urease test and histology).Safety was determined by the presence of adverse effects.RESULTS: Fifty-one patients were enrolled.The eradication rate was 68.8% (31/45).Adverse effects were reported by 31.4% of the patients,and these were usually considered to be slight or moderate in the majority of the cases.Three patients had to withdraw from the treatment due to the presence of severe adverse effects.CONCLUSION: The association of bismuth,furazolidone,amoxicillin and a proton-pump inhibitor is a valuable alternative for patients who failed to respond to other eradication regimens.It is an effective,cheap and safe option for salvage therapy of positive patients. AIM: To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success. METHODS: Open cohort study which included patients with peptic ulcer who had previously been treated unsuccessfully with one or more eradication regimens. The therapeutic regimen consisted of 20 mg omeprazole, 240 mg colloidal bismuth subcitrate, 1000 mg amoxicillin, and 200 mg furazolidone, taken twice a day for 7 d. Patients were considered as eradicated when samples taken from the gastric antrum and corpus 12 wk after the end of treatment were negative for Helicobacter pylori (H pylori) (rapid urease test and histology). Safety was determined by the presence of adverse effects. RESULTS: Fifty-one patients were enrolled. The eradication rate was 68.8% (31/45). Adverse effects were reported by 31.4% of the patients, and these were usually considered to be slight or moderate in the majority of the cases. Three patients had to withdraw from the treatment due to the presence of severe adverse effects.CONCLUSION: The association of bismuth, furazolidone, amoxicillin and a proton-pump inhibitor is a valuable alternative for patients who failed to respond to other eradication regimens. It is an effective, cheap and safe option for salvage therapy of positive patients.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第40期6224-6227,共4页 世界胃肠病学杂志(英文版)
关键词 Gastric ulcer Duodenal ulcer Helicobacter pylori RETREATMENT FURAZOLIDONE 胃溃疡 十二指肠溃疡 幽门 痢特灵
  • 相关文献

参考文献34

  • 1[1]Marshall BJ,Warren JR.Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.Lancet 1984; 1:1311-1315
  • 2[2]Malfertheiner P,Megraud F,O'Morain C,Bazzoli F,ElOmar E,Graham D,Hunt R,Rokkas T,Vakil N,Kuipers EJ.Current concepts in the management of Helicobacter pylori infection:the Maastricht Ⅲ Consensus Report.Gut 2007; 56:772-781
  • 3[3]Gisbert JP,Pajares JM.Review article:Helicobacter pylori infection and gastric outlet obstruction-prevalence of the infection and role of antimicrobial treatment.Aliment Pharmacol Ther 2002; 16:1203-1208
  • 4[4]Parente F,Cucino C,Bianchi Porro G.Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts.Dig Liver Dis 2003; 35:523-528
  • 5[5]Graham DY,Lew GM,Malaty HM,Evans DG,Evans DJ Jr,Klein PD,Alpert LC,Genta RM.Factors influencing the eradication of Helicobacter pylori with triple therapy.Gastroenterology 1992; 102:493-496
  • 6[6]Houben MH,van de Beek D,Hensen EF,Craen AJ,Rauws EA,Tytgat GN.A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates.Aliment Pharmacol Ther 1999; 13:1047-1055
  • 7[7]Mendonca S,Ecclissato C,Sartori MS,Godoy AP,Guerzoni RA,Degger M,Pedrazzoli J Jr.Prevalence of Helicobacterpylori resistance to metronidazole,clarithromycin,amoxicillin,tetracycline,and furazolidone in Brazil.Helicobacter 2000; 5:79-83
  • 8[8]White AH.Absorption,distribution,metabolism,and excretion of furazolidone.A review of the literature.Scand J Gastroenterol Suppl 1989; 169:4-10
  • 9[9]Fakheri H,Merat S,Hosseini V,Malekzadeh R.Lowdose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication.Aliment Pharmacol Ther 2004; 19:89-93
  • 10[10]Altamirano A,Bondani A.Adverse reactions to furazolidone and other drugs.A comparative review.Scand J Gastroenterol Supp1 1989; 169:70-80

同被引文献48

  • 1Qin-Juan Sun, Xiao Liang, Qing Zheng, Wei-Qi Gu, WenZhong Liu, Shu-Dong Xiao, Hong Lu.Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai[J].World Journal of Gastroenterology,2010,16(40):5118-5121. 被引量:91
  • 2彭国忠,黄夺夏,罗笑丹,彭旭.四联疗法治疗幽门螺杆菌阳性十二指肠溃疡患者的成本——效果分析[J].国际消化病杂志,2006,26(1):70-71. 被引量:6
  • 3成虹,胡伏莲,李江.幽门螺杆菌耐药性对其根除治疗影响的研究[J].中华医学杂志,2006,86(38):2679-2682. 被引量:97
  • 4刘治军,傅得兴,孙春华,迟家敏,张亚同.食物-药物相互作用[J].中国全科医学,2007,10(16):1350-1352. 被引量:12
  • 5Malfertheiner P, Megraud F, OMorain C, et al. Current con- cepts in the management of Helicobacter pylori infection: the MaastrichtⅢ Consensus Report[ J]. Gut, 2007, 56 (6) : 772- 81.
  • 6Eisig JN, Silva FM, Rodriguez TN, et al. A furazolidone- based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease [ J]. Clinics, 2005,60: 485- 488.
  • 7成虹,胡伏莲,谢勇,胡品津,王吉耀,吕农华,张建中,张桂英,周曾芬,吴克利,张玲霞,彭孝伟,戴宁,唐国都,姜葵,李岩,侯晓华,白文元,王明春,叶红军,刘玉兰,许乐.中国幽门螺杆菌耐药状况以及耐药对治疗的影响—全国多中心临床研究[J].胃肠病学,2007,12(9):525-530. 被引量:519
  • 8Ahmed HH,,El-Aziem SH,Abdel-Wahhab MA.Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats[].Toxicology.2008
  • 9L. GATTA, A. ZULLO&#8224,</a>, F. PERNA, C. RICCI, V. DE FRANCESCO&#8225,</a>, A. TAMPIERI, V. BERNABUCCI, M. CAVINA, C. HASSAN&#8224,</a>, E. IERARDI&#8225,</a>, S. MORINI&#8224,</a> &amp,D. VAIRA.A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses[].Alimentary Pharmacology and Therapeutics.2005
  • 10Zullo A,Hassan C,De Francesco V,Lorenzetti R,Marignani M,Angeletti S,Ierardi E,Morini S.A third-line levofloxacin- based rescue therapy for Helicobacter pylori eradication[].Digestive and Liver Disease.2003

引证文献9

二级引证文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部